AKAP-4: a novel cancer testis antigen for multiple myeloma - PubMed (original) (raw)
doi: 10.1111/j.1365-2141.2007.06940.x.
Raffaele Ferrari, Yuefei Yu, Cody Hamrick, Nicoletta Gagliano, Fabio Grizzi, Eldo Frezza, Marjorie R Jenkins, Fred Hardwick, Nicholas D'Cunha, W Martin Kast, Everardo Cobos
- PMID: 18217892
- DOI: 10.1111/j.1365-2141.2007.06940.x
Free article
AKAP-4: a novel cancer testis antigen for multiple myeloma
Maurizio Chiriva-Internati et al. Br J Haematol. 2008 Feb.
Free article
No abstract available
Similar articles
- CD138 shedding in plasma cell myeloma.
Grigoriadis G, Whitehead S. Grigoriadis G, et al. Br J Haematol. 2010 Aug;150(3):249. doi: 10.1111/j.1365-2141.2010.08203.x. Epub 2010 Apr 23. Br J Haematol. 2010. PMID: 20433680 No abstract available. - Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.
Armellini A, Sarasquete ME, García-Sanz R, Chillón MC, Balanzategui A, Alcoceba M, Fuertes M, López R, Hernández JM, Fernández-Calvo J, Sierra M, Megido M, Orfão A, Gutiérrez NC, González M, San Miguel JF. Armellini A, et al. Br J Haematol. 2008 Apr;141(2):212-5. doi: 10.1111/j.1365-2141.2007.06956.x. Br J Haematol. 2008. PMID: 18353163 Clinical Trial. - Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4.
Mirandola L, Yu Y, Jenkins MR, Chiaramonte R, Cobos E, John CM, Chiriva-Internati M. Mirandola L, et al. BMC Cancer. 2011 Sep 16;11:394. doi: 10.1186/1471-2407-11-394. BMC Cancer. 2011. PMID: 21923911 Free PMC article. - Direct AKAP-mediated protein-protein interactions as potential drug targets.
Hundsrucker C, Klussmann E. Hundsrucker C, et al. Handb Exp Pharmacol. 2008;(186):483-503. doi: 10.1007/978-3-540-72843-6_20. Handb Exp Pharmacol. 2008. PMID: 18491065 Review. - The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
Kehinde EO, Maghrebi MA, Anim JT. Kehinde EO, et al. Can J Urol. 2008 Apr;15(2):3967-74. Can J Urol. 2008. PMID: 18405443 Review.
Cited by
- A novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer.
Jagadish N, Parashar D, Gupta N, Agarwal S, Sharma A, Fatima R, Suri V, Kumar R, Gupta A, Lohiya NK, Suri A. Jagadish N, et al. Oncoimmunology. 2016 Feb 9;5(2):e1078965. doi: 10.1080/2162402X.2015.1078965. eCollection 2016 Feb. Oncoimmunology. 2016. PMID: 27057472 Free PMC article. - FSIP1 Is Associated with Poor Prognosis and Can Be Used to Construct a Prognostic Model in Gastric Cancer.
Yan X, Dai J, Han Y, You Q, Liu Y. Yan X, et al. Dis Markers. 2022 Jun 3;2022:2478551. doi: 10.1155/2022/2478551. eCollection 2022. Dis Markers. 2022. PMID: 35692888 Free PMC article. - The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma.
Agarwal S, Saini S, Parashar D, Verma A, Sinha A, Jagadish N, Batra A, Suri S, Gupta A, Ansari AS, Lohiya NK, Suri A. Agarwal S, et al. Oncoimmunology. 2013 May 1;2(5):e24270. doi: 10.4161/onci.24270. Epub 2013 Apr 1. Oncoimmunology. 2013. PMID: 23762804 Free PMC article. - Expression and clinical significance of A-kinase anchor protein 4 in lung adenocarcinoma tissue.
Li HM, Guo K, Yu XY, Yu Z, Xu P. Li HM, et al. Thorac Cancer. 2016 Apr 26;7(3):273-8. doi: 10.1111/1759-7714.12324. Epub 2015 Dec 16. Thorac Cancer. 2016. PMID: 27148411 Free PMC article. - Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
Yan M, Wang J, Ren Y, Li L, He W, Zhang Y, Liu T, Li Z. Yan M, et al. Cell Death Dis. 2019 Feb 27;10(3):204. doi: 10.1038/s41419-018-1248-8. Cell Death Dis. 2019. PMID: 30814489 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical